BioMarin Pharmaceutical Inc.
BMRN
$60.43
$1.903.25%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 3.22B | 3.09B | 3.06B | 2.95B | 2.85B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 3.22B | 3.09B | 3.06B | 2.95B | 2.85B |
| Cost of Revenue | 598.23M | 733.71M | 557.51M | 560.36M | 580.24M |
| Gross Profit | 2.62B | 2.36B | 2.51B | 2.39B | 2.27B |
| SG&A Expenses | 1.03B | 973.42M | 958.48M | 989.24M | 1.01B |
| Depreciation & Amortization | 19.39M | 24.19M | 24.35M | 33.81M | 43.26M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.57B | 2.48B | 2.29B | 2.33B | 2.38B |
| Operating Income | 650.73M | 615.50M | 776.08M | 619.65M | 474.21M |
| Income Before Tax | 482.48M | 679.27M | 840.04M | 674.31M | 541.76M |
| Income Tax Expenses | 133.58M | 158.86M | 182.80M | 150.42M | 114.90M |
| Earnings from Continuing Operations | 348.90 | 520.42 | 657.24 | 523.88 | 426.86 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 348.90M | 520.42M | 657.24M | 523.88M | 426.86M |
| EBIT | 650.73M | 615.50M | 776.08M | 619.65M | 474.21M |
| EBITDA | 722.89M | 698.22M | 859.33M | 710.79M | 570.64M |
| EPS Basic | 1.82 | 2.72 | 3.44 | 2.75 | 2.25 |
| Normalized Basic EPS | 2.36 | 2.22 | 2.75 | 2.21 | 1.75 |
| EPS Diluted | 1.78 | 2.67 | 3.38 | 2.70 | 2.20 |
| Normalized Diluted EPS | 2.31 | 2.16 | 2.67 | 2.13 | 1.68 |
| Average Basic Shares Outstanding | 767.13M | 765.59M | 763.99M | 762.20M | 760.10M |
| Average Diluted Shares Outstanding | 777.82M | 782.18M | 787.29M | 790.71M | 793.50M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |